Obesity is frequently occurring chronic disease caused by multiple factors and associated with severe comorbidities.
Lifestyle modifications (diet, physical activity) and behavioral therapy should always be first, preventive and therapeutic
approaches. At the opposite end of the therapeutic continuum stands bariatric/metabolic surgery. Therapeutic
gap between those approaches could change the anti-obesity drug therapy. Anti-obesity drug market situation is finally
changing. At present in the US for long-term chronic treatment of obesity FDA approved five drugs: orlistat, lorcaserin,
phentermine/topiramate ER naltrexone SR/bupropion SR and liraglutide 3.0 mg. In the EU we have currently
three approved drugs for chronic treatment of obesity: orlistat, a combination naltrexonSR/bupropion SR and liraglutide
3.0 mg. The future belong to such anti-obesity therapeutic strategy (monotherapy or combination therapy), which
will be equally effective in achieving and maintaining weight loss as a bariatric/metabolic surgery, will be safe with a minimum
of adverse events and at the same time will lead not only to influence cardiometabolic risk factors, but also to
decrease cardiovascular morbidity and mortality.